Vaccinex Inc., of Rochester, N.Y., said it will work with Darmstadt, Germany-based Merck KGaA to evaluate VX15/2503, an investigational humanized anti-semaphorin 4D antibody, in combination with avelumab, an investigational anti-PD-L1 antibody, in patients with advanced non-small-cell lung cancer who have not previously received immunotherapy.